
    
      Patients who demonstrate improvement in depressive symptoms at the end of the initial 12-week
      open-label treatment period with Levomilnacipran ER are randomized to continue
      Levomilnacipran ER or switch to placebo under double-blind conditions for up to 24 weeks of
      additional treatment.
    
  